Current status and future of targeted peptide receptor radionuclide positron emission tomography imaging and therapy of gastroenteropancreatic-neuroendocrine tumors

被引：0

作者：

Neil Grey ^{[1
]}

Michael Silosky ^{[2
]}

Christopher H Lieu ^{[3
]}

Bennett B Chin ^{[2
]}

机构：

[1] Radiology-Nuclear Medicine, University of Colorado School of Medicine, Anschutz Medical Campus

[2] Medical Oncology, University of Colorado School of Medicine, Anschutz Medical Campus

[3] Department of Radiology, University of Colorado School of Medicine, Anschutz Medical Campus

来源：

World Journal of Gastroenterology | 2022年 / 17期

关键词：

D O I：

暂无

中图分类号：

R735 [消化系肿瘤];

学科分类号：

100214 ;

摘要：

Theranostics is the highly targeted molecular imaging and therapy of tumors.Targeted peptide receptor radionuclide therapy has taken the lead in demonstrating the safety and effectiveness of this molecular approach to treating cancers.Metastatic, well-differentiated gastroenteropancreatic neuroendocrine tumors may be most effectively imaged and treated with DOTATATE ligands. We review the current practice, safety, advantages, and limitations of DOTATATE based theranostics. Finally, we briefly describe the exciting new areas of development and future directions of gastroenteropancreatic neuroendocrine tumor theranostics.

引用

页码：1768 / 1780

页数：13

共 50 条

[41] Efficacy of the Chronic Lanreotide Treatment of Gastroenteropancreatic Neuroendocrine Tumors (GEP/NET) after Peptide Receptor Radionuclide Therapy (PRRT)
Szalus, N.
Kaminski, G.
Podgajny, Z.
Dziuk, E.
NEUROENDOCRINOLOGY, 2009, 90 (01) : 137 - 137
[42] Hepatocellular Carcinoma and Gastroenteropancreatic Neuroendocrine Tumors: Potential Role of Other Positron Emission Tomography Radiotracers
Jadvar, Hossein
SEMINARS IN NUCLEAR MEDICINE, 2012, 42 (04) : 247 - 254
[43] Overview and Current Status of Peptide Receptor Radionuclide Therapy
Bushnell, David L.
Bodeker, Kellie L.
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2020, 29 (02) : 317 - +
[44] Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Decade of Experience
Kesavan, Murali
Turner, J. Harvey
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2016, 31 (06) : 189 - 198
[45] Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: Agonist, Antagonist and Alternatives
Santo, Giulia
Di Santo, Gianpaolo
Virgolini, Irene
SEMINARS IN NUCLEAR MEDICINE, 2024, 54 (04) : 557 - 569
[46] MYELOTOXICITY OF PEPTIDE RECEPTOR RADIONUCLIDE THERAPY OF NEUROENDOCRINE TUMORS: A DECADE OF EXPERIENCE
Kesavan, M.
Turner, J. H.
HAEMATOLOGICA, 2016, 101 : 776 - 777
[47] Peptide Receptor Radionuclide Therapy Combined With Chemotherapy in Patients With Neuroendocrine Tumors
Yordanova, Anna
Ahrens, Harriet
Feldmann, Georg
Brossart, Peter
Gaertner, Florian C.
Fottner, Christian
Weber, Matthias M.
Ahmadzadehfar, Hojjat
Schreckenberger, Mathias
Miederer, Matthias
Essler, Markus
CLINICAL NUCLEAR MEDICINE, 2019, 44 (05) : E329 - E335
[48] Positron emission tomography imaging in multiple sclerosis-current status and future applications
Kiferle, L.
Politis, M.
Muraro, P. A.
Piccini, P.
EUROPEAN JOURNAL OF NEUROLOGY, 2011, 18 (02) : 226 - 231
[49] Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Imaging Current Status, Future Aspects
Rakheja, Rajan
Chandarana, Hersh
Ponzo, Fabio
Seltzer, Alexandra L.
Beltran, Luis S.
Geppert, Christian
Friedman, Kent P.
PET CLINICS, 2014, 9 (02) : 237 - +
[50] SSTR-positive neuroendocrine tumors: peptide receptor radionuclide therapy
不详
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2023, 16 : S66 - S69

← 1 2 3 4 5 →